From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
HbA1c change from baseline (%)
BMI change from baseline (%)
Non-severe hypoglycaemia
(events per 100 patient-year)
Source
IDegLira
-1.66
0.04
24.00
DUAL I China
liraglutide
-1.04
-0.86
4
degludec
-1.13
0.43
17